Roth Affirms Ligand (LGND) at Buy; FDA Grants Promacta/Revolade Priority Review
Tweet Send to a Friend
Roth Capital affirms Ligand Pharmaceuticals (Nasdaq: LGND) at Buy with a price target of $92 following news that the U.S ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
